Along similar lines, rVSV-IFN-β was shown to induce a systemic antitumor immune response, marked by increased CD8+ tumor-infiltrating lymphocytes (TILs) and decreased Tregs and mMDSCs, in both injected and non-injected tumors, in a model of non-small cell lung cancer [107]. This evidence concerns the gene CD8A and neoplasm.